Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States ====================================================================================================== * Seth Flaxman * Charles Whittaker * Elizaveta Semenova * Theo Rashid * Robbie M Parks * Alexandra Blenkinsop * H Juliette T Unwin * Swapnil Mishra * Samir Bhatt * Deepti Gurdasani * Oliver Ratmann ## Abstract Covid-19 has caused more than 1 million deaths in the US, including at least 1,433 deaths among children and young people (CYP) aged 0-19 years. Deaths among US CYP are rare in general, and so we argue here that the mortality burden of Covid-19 in CYP is best understood in the context of all other causes of CYP death. Using publicly available data from the National Center for Health Statistics, and comparing to mortality in 2019, the immediate pre-pandemic period, we find that Covid-19 is a leading cause of death in CYP aged 0-19 years in the US, ranking #9 among all causes of deaths, #5 in disease related causes of deaths (excluding accidents, assault and suicide), and #1 in deaths caused by infectious / respiratory diseases. Due to the impact of mitigations such as social distancing and our comparison of a single disease (Covid-19) to groups of causes such as deaths from pneumonia and influenza, these rankings are likely conservative lower bounds. Our findings underscore the importance of continued vaccination campaigns for CYP over 5 years of age in the US and for effective Covid-19 vaccines for under 5 year olds. ## Introduction As of May 2022, more than 1 million individuals have died of Covid-19 in the US. In children and young people (CYP) aged 0-19 years, data from the National Center for Health Statistics (NCHS)1 indicate there were 1,433 deaths for which Covid-19 was the underlying cause of death (March 1, 2020-April 30, 2022). This is equivalent to 1.7 deaths per 100,000 population in this age group and an annualized rate of 0.8 per 100,000. The overall risk of death from Covid-19 in CYP is markedly reduced compared to other age groups in the US, e.g. 0.8 per 100,000 compared to a death rate of 89 per 100,000 population in 50-54 year olds. However, we argue here that in US CYP, deaths from all causes are rare (49.4 per 100,000 in 2019 for 0-19 year olds; 25.0 per 100,000 for 1-19 year olds), and so the mortality burden of Covid-19 is best understood by comparing it to other significant causes of CYP mortality from a recent pre-Covid-19 period. ## Methods We obtained leading causes of death by age group in 2019 from CDC Wonder2 and compared these to cumulative and annualized Covid-19 mortality spanning March 1, 2020-April 30, 2022. Cumulative mortality is a useful comparison as the first two years of the pandemic included significant non-pharmaceutical interventions which limited spread in the pre-Omicron period3, while annualized mortality may represent a lower bound on the future burden in the absence of widespread vaccination in pediatric age groups. To determine pediatric death rates by cause of death, we used 2020 population size estimates by single year of age from the US Census Bureau4. We note that NCHS’s leading causes of death group together many individual ICD codes, while Covid-19 deaths count only those for which a single ICD cause (U07.1) was the underlying cause of death; we are therefore comparing the direct effect of a *single* pathogen (SARS-CoV-2) to groupings of multiple diseases. Therefore, these rankings should be seen as conservative, especially in a situation of unmitigated spread. ## Results Like many diseases, pediatric Covid-19 death rates follow a U-shape in the US (cumulative death rates, March 1, 2020-April 30, 2022, Figure 1). Cumulative Covid-19 death rates peaked in infants aged <1 year at 7.2 deaths per 100,000 population. The cumulative Covid-19 death rate was 1.6 per 100,000 in 1-year old children, below 1 per 100,000 in children aged 2-12, gradually increasing to 3.9 per 100,000 in 18-year olds. Considering the marked, age-specific U-shape in pediatric Covid-19 death rates, we next compared the burden of Covid-19 to other causes of death in five age brackets: <1 year, 1-4 years, 5-9, 10-14, and 15-19 years1. Overall, Covid-19 ranks as the #7 (cumulative) and #9 (annualized) pediatric cause of death in US CYP aged 0-19 (Supplementary Table S1). Rankings disaggregated by age group are shown in Table 1, demonstrating that Covid-19 ranks consistently in the top 10 causes of death in all of the pediatric age groups. Cumulative ranks are: #4 (<1 year old), #5 (1-4 year olds), #5 (5-9 year olds), #4 (10-14 year olds), and #4 (15-19 year olds). Annualized ranks are: #8 (<1 year old), #7 (1-4 year olds), #6 (5-9 year olds), #6 (10-14 year olds), and #5 (15-19 year olds). ![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/05/27/2022.05.23.22275458/F1.medium.gif) [Figure 1.](http://medrxiv.org/content/early/2022/05/27/2022.05.23.22275458/F1) Figure 1. Covid-19 death rates in the US for children and young people, calculated using reports to NCHS of Covid-19 as an underlying cause of death (ICD code U07.1). Rates are calculated as Covid-19 deaths for the period March 1, 2020-April 30, 2022 per 100,000 population (2020 population estimates). View this table: [Table 1.](http://medrxiv.org/content/early/2022/05/27/2022.05.23.22275458/T1) Table 1. Leading causes of death for children and young people aged 0-19 years in 2019 in the US ranked, compared to Covid-19 deaths either as the cumulative total incidence of Covid-19 deaths for March 1, 2020-April 30, 2022 or as annualized figures. Deaths, crude rates per 100,000, and ranks are shown for ages < 1 year (a), 1-4 years (b), 5-9 years (c), 10-14 years (d), 15-19 years (e). In all cases, Covid-19 is a leading cause of death. The higher-ranking causes of pediatric deaths comprised perinatal conditions, congenital malformations or deformations, accidents, assault, diseases of the heart, malignant neoplasms, suicide, and influenza and pneumonia. Excluding causes of death unrelated to disease (accidents, assault and suicide), Covid-19 ranked as the #5 annualized cause of death in US CYP aged 0-19 (Supplementary Table S1). Considering infectious / respiratory diseases only, Covid-19 ranked as the #1 cause of death in US CYP aged 0-19 (Supplementary Table S2). ## Conclusion Early on in the Covid-19 pandemic, comparisons of Covid-19 disease severity between age groups were a vital tool for appropriately allocating limited resources and prioritizing vaccination campaigns. However, long-term public health planning and management needs to be informed by the leading causes of deaths within each age group. We have shown that Covid-19 was a leading cause of death in CYP aged 0-19 years in the US between March 2020 to April 2022, ranking #9 among all causes of deaths, #5 in disease related causes of deaths (excluding accidents, assault and suicide), and #1 in deaths caused by infectious / respiratory diseases. These findings need to be considered in the context of several limitations. Analyses of excess deaths have suggested under-reporting bias in Covid-19 deaths5. The criteria for determining Covid-19 deaths also vary across the US. Finally, some of the cause of death categories vary in specificity, for example, the category of deaths from “influenza and pneumonia” combines a variety of causes, to which SARS-CoV-2 would be a contributing factor6. Relatedly, we only consider Covid-19 as an underlying (and not contributing) cause of death, but Covid-19 amplifies the severe impacts of other diseases. It is thus likely that the burden of Covid-19 has been larger in CYP aged 0-19 than our analyses suggest. In summary, we find that Covid-19 is now a leading cause of death for CYP aged 0-19 in the US. A future variant capable of displacing Omicron will, by definition, have a growth advantage over Omicron, and there is no guarantee that its intrinsic severity will be reduced7. Our findings underscore the importance of continued vaccination campaigns for children ≥5 years in the US8 and for effective Covid-19 vaccines for under 5 year olds. ## Supporting information Supplementary Tables 1 and 2 and Supplementary Figure 1 [[supplements/275458_file03.pdf]](pending:yes) ## Data Availability All data were originally obtained from https://wonder.cdc.gov/ and https://data.cdc.gov/api/views/3apk-4u4f and are available online at https://github.com/flaxter/covid19pediatric/ [https://wonder.cdc.gov/](https://wonder.cdc.gov/) [https://data.cdc.gov/api/views/3apk-4u4f](https://data.cdc.gov/api/views/3apk-4u4f) [https://github.com/flaxter/covid19pediatric/](https://github.com/flaxter/covid19pediatric/) ## Ethics According to HRA decision tools ([http://www.hra-decisiontools.org.uk/research/](http://www.hra-decisiontools.org.uk/research/)), our study is considered Research, and according to the NHS REC review tool ([http://www.hra-decisiontools.org.uk/ethics/](http://www.hra-decisiontools.org.uk/ethics/)), we do not need NHS Research Ethics Committee (REC) review, as we only used (1) publicly available, (2) anonymized, and (3) aggregated data outside of clinical settings. ## Funding ES and SF acknowledge funding from the EPSRC (EP/V002910/2), OR from the MRC (MR/V038109/1). SM and SB acknowledge funding from the Novo Nordisk Young Investigator Award (NNF20OC0059309). CW acknowledges funding from the MRC DTP that supports his PhD studies (Award Ref 1975152). This research was funded in whole or in part by EPSRC (EP/V002910/2). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript (AAM) version arising from this submission. ## Code Availability All data and R scripts for replicating the results in this manuscript are available from: [https://github.com/flaxter/covid19pediatric/](https://github.com/flaxter/covid19pediatric/) ## Footnotes * Calculations for annualized totals changed to a 26 month period rather than a 25 month period; Tables sorted by death counts rather than rates; Figure 1 caption clarified; Supplementary Figure 1 added. * Received May 23, 2022. * Revision received May 27, 2022. * Accepted May 27, 2022. * © 2022, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) ## References 1. 1.NCHS/DVS. Provisional COVID-19 Death Counts by Age in Years, 2020-2022 [Internet]. 2020 [cited 2022 May 9];Available from: [https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Age-in-Years-/3apk-4u4f](https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Age-in-Years-/3apk-4u4f) 2. 2.Underlying cause of death, 1999-2020 request [Internet]. [cited 2022 May 13];Available from: [http://wonder.cdc.gov/ucd-icd10.html](http://wonder.cdc.gov/ucd-icd10.html) 3. 3.Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection-and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA 2021;326(14):1400–9. 4. 4.US Census Bureau. National Demographic Analysis Tables: 2020. 2022 [cited 2022 May 16];Available from: [https://www.census.gov/data/tables/2020/demo/popest/2020-demographic-analysis-tables.html](https://www.census.gov/data/tables/2020/demo/popest/2020-demographic-analysis-tables.html) 5. 5.Whittaker C, Walker PGT, Alhaffar M, et al. Under-reporting of deaths limits our understanding of true burden of covid-19. BMJ 2021;375:n2239. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzUvb2N0MTJfMi9uMjIzOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA1LzI3LzIwMjIuMDUuMjMuMjIyNzU0NTguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 6. 6.Swets MC, Russell CD, Harrison EM, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet 2022;399(10334):1463–4. 7. 7.Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat Rev Microbiol 2022;20(5):251–2. 8. 8.Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med 2022;386(1):35–46. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/nejmoa2116298&link_type=DOI)